{"id":"W2192931230","doi":"10.1158/1078-0432.ccr-15-1221","title":"A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":71,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Response Evaluation Criteria in Solid Tumors; Peripheral edema; Pharmacodynamics; Adverse effect; Internal medicine; Angiopoietin receptor; Gastroenterology; Refractory (planetary science); Antibody; Pharmacology; Toxicity; Oncology; Angiogenesis; Phases of clinical research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001247194,0.001788591,0.001444085,0.0003045395,0.000390588,0.0006990134,0.0005751331,0.0008507574,0.002562689],"category_scores_gemma":[0.0006438982,0.0006149509,0.000895361,0.0002279633,0.0009062621,0.0006851569,0.000244942,0.002477252,0.0005996781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009420916,"about_ca_system_score_gemma":0.001177109,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006172907,"about_ca_topic_score_gemma":0.00159164,"domain_scores_codex":[0.9995915,0.0002057405,0.00001730277,0.00006805695,0.00003968939,0.00007769872],"domain_scores_gemma":[0.9994579,0.00009446139,0.000109815,0.00005509853,0.00004053794,0.0002422262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5267737,0.1648826,0.01007024,0.001454034,0.00178531,0.000719698,0.0007282937,0.006049462,0.1585652,0.0004824452,0.005270372,0.1232187],"study_design_scores_gemma":[0.3506104,0.6193421,0.01241961,0.00003141574,0.0003210076,0.0005703826,0.0000608657,0.001537604,0.01164872,0.0001726257,0.003252157,0.00003320218],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993922,0.001175735,0.0007506015,0.0001655094,0.00006415118,0.002122507,0.0006815094,0.00005729607,0.001060814],"genre_scores_gemma":[0.9909239,0.001252569,0.001669431,0.0004335617,0.0001098226,0.001683055,0.00173427,0.00003038446,0.002162942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002562689,"threshold_uncertainty_score":0.008573115,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1156749515187689,"score_gpt":0.5107361207049393,"score_spread":0.3950611691861704,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}